These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 22498670)

  • 21. Invasive urothelial carcinoma exhibiting basal cell immunohistochemical markers: A variant of urothelial carcinoma associated with aggressive features.
    Mai KT; Truong LD; Ball CG; Williams P; Flood TA; Belanger EC
    Pathol Res Pract; 2015 Aug; 211(8):610-8. PubMed ID: 26100813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2.
    McCluggage WG; Shah R; Connolly LE; McBride HA
    Int J Gynecol Pathol; 2008 Jan; 27(1):92-100. PubMed ID: 18156982
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Carcinoma In Situ With Plasmacytoid Features: A Clinicopathologic Study of 23 Cases.
    Sangoi AR; Falzarano SM; Nicolas M; McKenney JK
    Am J Surg Pathol; 2019 Dec; 43(12):1638-1643. PubMed ID: 31368912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nested and microcystic variants of urothelial carcinoma displaying immunohistochemical features of basal-like urothelial cells: an immunohistochemical and histopathogenetic study.
    Mai KT; Hakim SW; Ball CG; Flood TA; Belanger EC
    Pathol Int; 2014 Aug; 64(8):375-81. PubMed ID: 25143125
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A proposed score for assessing progression in pT1 high-grade urothelial carcinoma of the bladder.
    Raspollini MR; Minervini A; Lapini A; Lanzi F; Rotellini M; Baroni G; Carini M
    Appl Immunohistochem Mol Morphol; 2013 May; 21(3):218-27. PubMed ID: 22820663
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mixed low- and high-grade papillary urothelial carcinoma: histopathogenetic and clinical significance.
    Mai KT; Flood TA; Williams P; Kos Z; Belanger EC
    Virchows Arch; 2013 Oct; 463(4):575-81. PubMed ID: 23913166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular and immunohistologic analyses cannot reliably solve diagnostic variation of flat intraepithelial lesions of the urinary bladder.
    Murata S; Iseki M; Kinjo M; Matsuzaki O; Moriuchi A; Ohtani H; Sakurai T; Satake T; Tsuzuki T
    Am J Clin Pathol; 2010 Dec; 134(6):862-72. PubMed ID: 21088148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comprehensive Gene Expression Analyses of Immunohistochemically Defined Subgroups of Muscle-Invasive Urinary Bladder Urothelial Carcinoma.
    Kim B; Jang I; Kim K; Jung M; Lee C; Park JH; Kim YA; Moon KC
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inverse p16 and p63 expression in small cell carcinoma and high-grade urothelial cell carcinoma of the urinary bladder.
    Buza N; Cohen PJ; Pei Hui ; Parkash V
    Int J Surg Pathol; 2010 Apr; 18(2):94-102. PubMed ID: 20164052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of basal cell status and proliferative patterns in flat and papillary urothelial lesions: a contribution to the new WHO classification of the urothelial tumors of the urinary bladder.
    Helpap B; Köllermann J
    Hum Pathol; 2000 Jun; 31(6):745-50. PubMed ID: 10872670
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnosis of urothelial carcinoma in situ using blue light cystoscopy and the utility of immunohistochemistry in blue light-positive lesions diagnosed as atypical.
    Pederzoli F; Murati Amador B; Samarska I; Lombardo KA; Kates M; Bivalacqua TJ; Matoso A
    Hum Pathol; 2019 Aug; 90():1-7. PubMed ID: 31071342
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytokeratin 20 immunocytochemistry on urine sediments: A potential low-cost adjunct to cytology in the diagnosis of low-grade urothelial carcinoma.
    Wadhwa N; Diwaker P; Lotha N; Arora VK; Singh N
    Cytopathology; 2017 Dec; 28(6):531-535. PubMed ID: 28940433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Utility of ProEx C in the histologic evaluation of the neoplastic and nonneoplastic urothelial lesions.
    Moatamed NA; Vergara-Lluri ME; Lu D; Apple SK; Kerkoutian S; Rao JY
    Hum Pathol; 2013 Nov; 44(11):2509-17. PubMed ID: 24029711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia.
    Desai S; Lim SD; Jimenez RE; Chun T; Keane TE; McKenney JK; Zavala-Pompa A; Cohen C; Young RH; Amin MB
    Mod Pathol; 2000 Dec; 13(12):1315-23. PubMed ID: 11144928
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur.
    Barbisan F; Santinelli A; Mazzucchelli R; Lopez-Beltran A; Cheng L; Scarpelli M; van der Kwast T; Montironi R
    Cancer; 2008 Feb; 112(3):636-44. PubMed ID: 18072261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bladder Tumor Subtype Commitment Occurs in Carcinoma
    Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
    Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transcriptional Analysis of Immunohistochemically Defined Subgroups of Non-Muscle-Invasive Papillary High-Grade Upper Tract Urothelial Carcinoma.
    Jung M; Lee JH; Kim B; Park JH; Moon KC
    Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30699951
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains.
    Tamas EF; Epstein JI
    Am J Surg Pathol; 2007 Mar; 31(3):390-7. PubMed ID: 17325480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemiocal subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis.
    Sikic D; Keck B; Wach S; Taubert H; Wullich B; Goebell PJ; Kahlmeyer A; Olbert P; Isfort P; Nimphius W; Hartmann A; Giedl J;
    PLoS One; 2017; 12(6):e0179602. PubMed ID: 28632777
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic and prognostic roles of CK20 in the pathology of urothelial lesions. A systematic review.
    Sanguedolce F; Russo D; Calò B; Cindolo L; Carrieri G; Cormio L
    Pathol Res Pract; 2019 Jun; 215(6):152413. PubMed ID: 30987832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.